This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

41/100

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objectives Neurofilament light chain (NfL) conventionally reflects disability worsening in multiple sclerosis (MS), but does not necessarily imply MS-specific mechanisms and could be affected by biological or pathological aging, including Alzheimer disease (AD) pathology. We aim to evaluate clinical correlates of plasma NfL (pNfL) in elderly patients with MS, and its associations with AD plasma biomarkers. Methods We recruited consecutive people with MS >65 years, and collected expanded disability status scale (EDSS), current disease modifying treatment (DMT) and years of exposure to DMTs.

What this study adds

Evidence grade: Low

The record lists 83 participants. This study looked at a blood marker of nerve damage and Alzheimer's blood biomarkers in people over 65 who have multiple sclerosis. It is about measuring biomarkers in this group, not about treating, curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Novarella, F., Nicolella, V., Fiorenza, M., Falco, F., Monteiro, I., Corsini, G., et al. (2025). Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis. Journal of the neurological sciences. https://doi.org/10.1016/j.jns.2025.123562

Vancouver

Novarella F, Nicolella V, Fiorenza M, Falco F, Monteiro I, Corsini G, et al. Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis. Journal of the neurological sciences. 2025. doi:10.1016/j.jns.2025.123562. PMID: 40482625.

BibTeX

@article{novarella2025-40482625,
  author  = {Novarella, F. and Nicolella, V. and Fiorenza, M. and Falco, F. and Monteiro, I. and Corsini, G. and Ranucci, D. and Carotenuto, A. and others},
  title   = {{Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis}},
  journal = {Journal of the neurological sciences},
  year    = {2025},
  doi     = {10.1016/j.jns.2025.123562},
  pmid    = {40482625},
  url     = {https://doi.org/10.1016/j.jns.2025.123562}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 83 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

We aim to evaluate clinical correlates of plasma NfL (pNfL) in elderly patients with MS, and its associations with AD plasma biomarkers.
Methods We recruited consecutive people with MS >65 years, and collected expanded disability status scale (EDSS), current disease modifying treatment (DMT) and years of exposure to DMTs.
Cognitive function was assessed using the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-II (CVLT-II), and the Brief Visuospatial Memory Test-Revised (BVMTR).
Plasma biomarkers (Aβ40, Aβ42, p-Tau181, and pNfL) were measured using LUMIPULSE assay kits on the CLEIA analyser LUMIPULSE G600II.

Why it matters

This study looked at a blood marker of nerve damage and Alzheimer's blood biomarkers in people over 65 who have multiple sclerosis. It is about measuring biomarkers in this group, not about treating, curing or preventing Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants83
Evidence strengthLow

How this study scored 41/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of the neurological sciences)
Journal's citation record	2 / 4	Journal of the Neurological Sciences: journal h-index 233 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	1 / 4	83 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 7 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.3 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 4.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Marcello Moccia: h-index 48 (OpenAlex, whole career)
Institution's track record	1 / 3	Sapienza University of Rome: institution h-index 1,145 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40482625)
Free to read	0 / 2	Behind a paywall — scores zero
Total	41 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →